External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)

Chronic Pain Clinical Trial

— XANADO  

Official title:

External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05537662
• Other study ID #: ABT-CIP-10458
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 2023
• Est. completion date: April 2025

Study information

• Verified date: March 2023
• Source: Abbott Medical Devices
• Contact: Ameya Nanivadekar
• Phone: (972) 309-2103
• Email: Ameya.nanivadekar[@]abbott.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, longitudinal, single-center, non-randomized, open-label, post-market clinical feasibility study to assess the efficacy of neuromodulation therapies (SCS and DRG) for chronic pain patients with diabetes and investigate whether physical and physiological data collected from diabetic and pre-diabetic chronic pain patients is predictive of subjective patient-reported outcomes (PROs) and of adjustments in patient care. These assessments will be made prior to, during, and after the trial of the SCS or DRG system. The study will be carried out in the United States at a single site.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: April 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject must provide written informed consent prior to any clinical investigation-related procedure.

2. Subject is at least 18 years of age or older at the time of enrollment.

3. Subject's scheduled trial duration for the Abbott neuromodulation system is at least 7 days.

4. Subject is scheduled to undergo trial of an Abbott neuromodulation system for chronic intractable back and/or leg pain at least 7 days after enrollment and commencement of the baseline data collection period.

5. Subject agrees to take an A1C screening test prior to study enrollment and has a confirmed HbA1C level = 5.7%.

6. Subject has a baseline (with no stimulation) pain NRS of = 6.

7. Subject is willing to cooperate with the study requirements including completion of all office visits.

8. Subject agrees to wear the wearable sensing devices (Fitbit® and Freestyle Libre).

9. Subject agrees to answer questionnaires regularly for the duration of the study.

Exclusion Criteria:

1. Subject is enrolled, or intends to participate, in a competing or confounding clinical study, as determined by Abbott.

2. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.

3. Subject is part of a vulnerable population.

4. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results.

5. Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, post-herpetic neuralgia.

6. Subject has, or is scheduled to receive, implantation of another neuromodulation system (e.g. DRG or SCS system or intrathecal pump) to address their chronic pain.

7. Subject has already participated in a SCS trial period before enrolling in the study.

8. Subject engages in a profession or other activity that could be damaging to the wearable sensors, as determined by the investigator.

9. Subject has a physical condition that makes it difficult to wear the wearable sensors, as determined by the investigator.

10. Subject has tremors (e.g. Parkinson's disease or Familial tremors).

11. Subject has sleep/wake schedule that would present a challenge in completing all clinical site visits or in use of the wearable devices and engagement in the surveys via the mobile device.

12. Subject is bedridden.

Related Conditions & MeSH terms

• Chronic Pain

Intervention

Device:
• Standard of care neuromodulation therapy (SCS or DRG)
Standard SCS or DRG therapy

Locations

Country	Name	City	State
United States	Rush University Medical Center	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The mean change in pain scores measured by the Numerical Rating Scale (NRS) at baseline and follow up at 3 months	Change in physical activity levels, pain interference and decreased sleep quality with reported pain, performance of tasks, association of facial recognition analysis with reported pain, need for reprogramming or other therapeutic interventions or termination of neuromodulation.	At 3 month
Primary	The mean change in pain scores measured by the Numerical Rating Scale (NRS) at baseline and follow up at 6 months	Change in physical activity levels, pain interference and decreased sleep quality with reported pain, performance of tasks, association of facial recognition analysis with reported pain, need for reprogramming or other therapeutic interventions or termination of neuromodulation.	At 6 month